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Abstract  31 
Objective: Diagnostic screening for functional neurological disorders (FNDs) continues to 32 
pose a challenge. Simple symptom counts fail clearly to discriminate patients with FND but 33 
there is increasing recognition of ‘positive’ features which are useful diagnostically during 34 
face-to-face assessments. A self-completed screening questionnaire evaluating specific 35 
features of FNDs would be useful for screening purposes in clinical and research settings. 36 
Methods: The Edinburgh Neurosymptoms Questionnaire (ENS) is a 30-item survey of 37 
presence and nature of: blackouts, weakness, hemisensory syndrome, memory problems, 38 
tremor, pain, fatigue, globus, multiple medical problems, and operations constructed via 39 
literature review and expert consensus. We conducted a pilot of the ENS on new general 40 
neurology clinic attendees at a large regional neuroscience centre. Patients were grouped 41 
according to consultant neurologist impression as having symptoms that were ‘Not at 42 
all’, ’Somewhat’, ’Largely’ or ’Completely’ due to a functional disorder.  43 
Results: Blackouts, weakness and memory questions provided reasonable diagnostic utility 44 
(AUROC = 0.94, 0.71, 0.74 respectively) in single symptom analysis. All other symptoms 45 
lacked discriminating features. A multivariate linear model with all symptoms predicted 46 
functional classification with moderate diagnostic utility (AUROC = 0.83), specificity of 0.97, 47 
sensitivity of 0.47. Pain and blackout scores provided the most accurate predictor of 48 
functional classification. 49 
Conclusion: The ENS questionnaire provides some utility in differentiating patients 50 
presenting with functional blackouts but failed to provide diagnostic value in other types of 51 
FND highlighting the limitations of this self-report tool.  52 
 53 
Key Words: Functional Neurological Disorders, Symptom Count, Screening Questionnaire, 54 
Neurological Symptoms, Neuropsychiatry. 55 
 56 
Highlights: 57 
• A novel screening questionnaire for functional neurological disorders (FNDs). 58 
• Gross symptom count provided no diagnostic utility in FNDs (AUC = 0.60). 59 
• Questions regarding positive features of FND provide modest utility (AUC = 0.83). 60 
Introduction 61 
Functional Neurological Disorders (FNDs) have historically been considered a common but 62 
challenging diagnosis [1], with a considerable impact on patient quality of life [2]. They are 63 
characterised by a deficit in neurological functioning rather than a pathophysiological lesion 64 
which may affect any faculty including movement, sensation or cognition. Patients with 65 
symptoms without a pathophysiological cause comprise 30% of general neurology 66 
outpatients [3] and between 16-34% of primary care attendees [4–6]. They are commonly 67 
undiagnosed [7–10], over-investigated [7,11,12], and report poor clinical outcomes 68 
[2,13,14]. 69 
 70 
Although challenging for a variety of reasons [7], there is a growing body of 71 
literature describing the reliable diagnosis of FNDs if undertaken by clinicians appropriately 72 
trained in neurological assessment [15]. It is a diagnosis based upon positive signs of 73 
neurological deficit, inconsistent with pathophysiologically explained neurological disease. 74 
Examples include: Hoover’s Sign, in which a deficit in voluntary hip extension is reversed 75 
with contralateral hip flexion; the tremor entrainment test, in which the frequency of 76 
tremor may be entrained to that of an externally cued rhythmic movement of the 77 
contralateral arm. Recent work [16–18] has described the diagnostic value of these and 78 
other signs, which in a pilot sample provided specificities and sensitivities of 100% and 95% 79 
respectively, for a variety of functional disorders [19]. However, the dependency of 80 
diagnosis being based on a clinical assessment by an experienced clinician trained in 81 
neurological examination, limits reliability of diagnosis in primary care [20], and is financially 82 
prohibitive to the conduct of large cohorts studies. Ideally a brief questionnaire is needed 83 
with acceptable specificity and sensitivity for community epidemiology and to improve pre-84 
test probability in primary care, but no such scale currently exists.  85 
 86 
There have been several self-report questionnaire approaches to assessing somatic 87 
symptoms [21], the Patient Health Questionnaire-15 (PHQ-15) [22] being perhaps the most 88 
widely used, including in the validation of DSM-5 cross-cutting assessments [23,24]. These 89 
scores, although not initially intended for diagnostic use, have been applied [25,26] to the 90 
prediction of somatoform disorder, but seldom tested against gold standard clinical 91 
assessments. In FNDs specifically however, these tools fail to discriminate 92 
pathophysiological or “organic” from functional neurological disorders and perform little 93 
better than chance when tested against clinical examination by a neurologist [27]. The 94 
performance of such symptom counts was not enhanced by the addition of items measuring 95 
various features of psychopathology. 96 
 97 
Alternate approaches assessing specific clinical features by questionnaire have been 98 
more promising. Self-reported features of transient loss of consciousness using an extensive 99 
86-item tool could predict, with accuracy, a diagnosis of syncope, psychogenic non-epileptic 100 
seizures and epilepsy with sensitivities and specificities ranging from 80-95% and 74-93% 101 
between diagnoses [28]. Erba et al [29] similarly showed diagnostic utility in a range of self-102 
reported seizure features in patients with epilepsy vs psychogenic non-epileptic seizures, 103 
including: triggering headache; premonitory racing heart or numbness/tingling; post-ictal 104 
physical pain and a history of head injury with loss of consciousness > 5mins, physical abuse 105 
or fatigue. There have so far been no attempts to construct a short, self-report 106 
questionnaire for the prediction of a functional neurological disorders in general. Such a 107 
questionnaire could be used to increase pre-test probabilities of a functional disorder 108 
diagnosis and assist in epidemiological research. We would not expect that a questionnaire 109 
would, or should, replace clinical diagnosis. 110 
 111 
We therefore piloted a 30-item questionnaire that synthesised recognised diagnostic 112 
features of the neurological history in people with FND with the aim of developing a 113 




We recruited from consecutive, newly referred general neurology patients who attended a 118 
clinic appointment at the Department of Clinical Neurosciences, Western General Hospital, 119 
Edinburgh in a 4-week period between September and October 2017. Prospective 120 
participants were sent an information letter in the post with their appointment describing 121 
the aims and nature of the study. All patients were approached and consented in the 122 
waiting room. Patients were excluded if: they were under 16, they did not attend their 123 
appointment, they had cognitive impairment or insufficient English language skills to 124 
provide informed consent or completion of the survey. Ethical approval for the study was 125 
granted by South East Scotland Research Ethics Committee. 126 
Survey Design 127 
Expert consensus between authors JS, ME, MR, IH and AC with extensive clinical experience 128 
of the patients and a literature review [30] was used to construct a 30-item questionnaire of 129 
possible discriminating questions (Appendix A) which could be completed in under 10 130 
minutes. Symptom features identified from the literature with evidence of positive 131 
diagnostic utility were: 132 
- Blackouts: Lying still or shaking; Episodes in a medical setting [31]; More than two 133 
seizures lasting more than 10 minutes [32–34]; Ability to hear but not respond during a 134 
blackout [18]; Pre-ictal dissociative symptoms [35]; Postictal crying/upset [32]. 135 
- Weakness: Dropping things frequently; Variable severity; Worsening of weakness with 136 
attention [36]; Prodromal anxiety [37,38]; Associated depersonalisation [39]; 137 
- Memory Problems: Forgetting important details of everyday life[40]; Blank spells 138 
occurring during the day [40]; Oneself more bothered than others; 139 
- Tremor: Sudden onset [41]; Precipitating traumatic event [37]; Variable severity [41]; 140 
Distractibility [42]. 141 
- Pain: Variable location and severity [43]. 142 
- Fatigue: Worsened by activity [43]. 143 
Patients only had to complete sub-questions regarding a symptom if they had reported 144 
experiencing the symptom as a “stem” question. 145 
 146 
We also included questions about the presence of certain symptoms and features of 147 
clinical history that in themselves may be predictive of a functional disorder. These included 148 
hemisensory syndrome (‘Do you have numbness or altered sensation that makes you feel 149 
like your body is cut in half?’) [44], globus [45], stutter [46,47], multiple medical problems 150 
[48], and particular operations such as hysterectomy, appendicectomy, laparoscopy or 151 
tonsillectomy [49,50]. These items did not have differentiating sub-questions. Demographic 152 
data including sex and age were also collected. 153 
 154 
Diagnosis and Rating of explanation with respect to functional disorder 155 
We asked neurologists to provide 1) their provisional diagnosis and 2) their assessment of 156 
the extent to which the patients’ symptoms were related to a functional disorder. 157 
Functional neurological disorders remain a taxonomic challenge and often exist in a 158 
spectrum, concomitant with pathophysiological disease. For this reason, patients were 159 
scored according to a 4-point Likert scale: ‘Not at All’, ‘Somewhat’, ‘Largely’ and 160 
‘Completely’ by clinicians in response to the question: “To what extent do you think the 161 
patient’s clinical symptoms are explained by a functional disorder?”. Wording of this 162 
question encompassed the entire clinical presentation not just the presenting symptom. 163 
Definitions of functional disorders were supplied to clinicians as a guide to diagnostic 164 
categorisation (Appendix B). A graded classification like this allows for a broader evaluation 165 
of patients which may have symptoms without a pathophysiological cause but not a primary 166 
functional diagnosis. Note this question was an evolution of previous categorisations from 167 
our research group as 'not explained by disease' [3]. We were keen to move away from 168 
defining disorders by the absence of disease since they have their own positive diagnostic 169 
features, now recognised in DSM-5 criteria for Functional Neurological Symptom Disorder.  170 
Clinical assessment of these features by an experienced neurologist is the current diagnostic 171 
gold standard for FND [51], with misdiagnosis rates quantified as 0.4% in a large cohort of 172 
new neurology outpatients [3]. 173 
Questionnaire Analysis 174 
For the purposes of analysis, patients were grouped into having symptoms classed as ‘Not at 175 
all/Somewhat’ and ‘Largely/Completely’ due to a functional disorder. Univariate analysis 176 
was undertaken on individual questions by cross-tabulation and significance testing using 177 
Fisher’s Exact test. Symptom and gross ENS score were assessed using two-tailed Student’s 178 
t-tests. Multivariate analysis was undertaken via logistic regression. We first analysed the 179 
diagnostic utility of sub-questions in predicting classification of ‘Largely’ or ‘Completely’ 180 
functional for reporters of a particular symptom. Linear models for each symptom were 181 
used to return a score for likelihood of functional classification. Scores from these 182 
symptoms were then combined in an aggregate model with symptoms and features that did 183 
not have sub-questions and demographic data to provide an overall score. This method 184 
introduces a significant positive bias into the second round of modelling, as symptoms with 185 
sub-questions have already been weighted towards predicting a functional outcome. 186 
Alternative options such as hierarchical logistic regression and stratifying patients by 187 
reported symptoms were prohibited by sample size and the number of potential symptom 188 
combinations. We justify this method as exploratory and speculative in the context of a pilot 189 
that aims to obtain a broad picture of the potential utility of a general screening tool. 190 
Questions which provided perfect or quasi-separation were excluded from multivariate 191 
analysis and their contribution assessed during univariate analysis only. All analysis was 192 
conducted in MATLAB© Release 2015b using custom written scripts. 193 
Results 194 
Data were gathered on 165 patients, 56 (34%) participants had data missing and were 195 
excluded leaving 109 (Age = 44.6 ± 17.1 years; Female:Male Ratio = 1.53:1) responses 196 
available for analysis. 104/109 (95%) of those surveyed responded having at least one of the 197 
symptoms included in the questionnaire. 198 
 199 
73/109 (67%) patients were classed as having symptoms ‘Not at All/Somewhat (N/S)’ 200 
and 36/109 (33%) as ‘Largely/Completely (L/C)’ due to a functional disorder. The most 201 
common diagnoses made in those classified as ‘Not at All/Somewhat’ were: Epilepsy 16/109 202 
(15%), Migraine 11/109 (10%), peripheral neuropathy or radiculopathy 9/109 (8%), 203 
headache syndromes 6/109 (6%), first seizure 6/109 (6%) and demyelinating disease 5/109 204 
(5%). In those classified as ‘Largely/Completely’: dissociative seizures 9/109 (8%), functional 205 
weakness 3/109 (3%), functional sensory changes 3/109 (3%), anxiety related symptoms 206 
3/109 (3%), functional memory symptoms 1/19 (1%) and FND not otherwise specified 2/109 207 
(2%) were the most common diagnoses.  Female:Male ratio differed significantly between 208 
groups (N/S = 1.09:1; L/C = 3.5:1; Fisher’s Exact p = 0.01) whilst age did not (N/S = 46 ± 17.5; 209 
L/C = 41.6 ± 16.2; two-tailed Student’s t-test p = 0.20). 210 
 211 
The 56 participants excluded from analysis due to incomplete questionnaires or 212 
consultant diagnosis were marginally older than those included (47.15 ± 17.1 vs 44.6 ± 16.83 213 
years; Student’s t-test p = 0.36) and had a greater F:M ratio (2.31:1 vs 1.53:1; Chi-square p = 214 
0.72). 15/56 were excluded for lack of diagnostic outcome data, of those remaining 28/41 215 
(68%) were classed as having symptoms ‘Not at all/Somewhat’ due to a functional disorder 216 
and 13/41 (32%), similar proportions to those included in analysis (Chi-square p = 0.88). 217 
 218 
Univariate Analysis: Few questions provide diagnostic utility and gross scores fail to 219 
discriminate patients. 220 
Answers to all symptom questions and sub-questions are displayed in Table 1. Some 221 
symptoms were reported significantly more frequently by those classed as 222 
‘Largely/Completely’ functional, including: hemisensory disturbance (N/S = 8/73 (11%); L/C 223 
= 11/36 (31%); p = 0.02), tremor (N/S = 19/73 (11%); L/C = 17/36 (31%); p = 0.02), pain (N/S 224 
= 24/73 (33%); L/C = 22/36 (61%); p = 0.007), fatigue (N/S = 40/73 (55%); L/C = 28/36 (78%); 225 
p = 0.02). 226 
 227 
5/20 symptom features were reported significantly more often by patients classed as 228 
‘Largely/Completely’ related to a functional disorder including: having had a blackout in a 229 
medical setting (N/S = 1/21 (5%); L/C = 5/9 (56%); p = 0.005); being able to hear others but 230 
not respond during a blackout (N/S = 5/21 (24%); L/C = 8/9 (89%); p = 0.002); crying or being 231 
upset after a blackout (N/S = 5/21 (24%); L/C = 6/9 (67%); p = 0.04); having blank spells 232 
occurring throughout the day if also experiencing memory problems (N/S = 12/39 (31%); L/C 233 
= 15/22 (68%); p = 0.007) and experiencing pain that is variable in severity and location (N/S 234 
= 10/24 (42%); L/C = 16/22 (73%); p = 0.04). 235 
 236 
Gross symptom count was significantly different between ‘N/S’ and ‘L/C’ patients 237 
(N/S = 3.15 ± 2.07; L/C = 4.33 ± 2.27; 2-Tailed Student’s t-test p = 0.008) (Figure 1A) but 238 
without diagnostic utility (Receiver-operator characteristic area under the curve (AUC) = 239 
0.595). Raw Edinburgh Neurosymptom Score (ENS) scores, which include the addition of 240 
sub-questions designed to provide a positively discriminating score, yields greater gross 241 
scores for ‘L/C’ patients, again significantly so (N/S = 7.95 ± 5.48; L/C = 11.69 ± 7.27; 2-Tailed 242 
Student’s t-test p = 0.003) (Figure 1B) but again without diagnostic utility (AUC = 0.602).  243 
 244 
Multivariate sub-question analysis: Blackouts may be amenable to questionnaire 245 
diagnosis, but other symptom groups lack discriminating questions. 246 
Logistic regression analysis of individual “common” symptoms is described in Figure 2. Only 247 
three sub-questions obtained significance during multivariate analysis. Q1d: “Have you ever 248 
been able to hear people but not respond to them during your blackout?” (p = 0.047; OR = 249 
20.72 (0.88-487.97)), Q4c: “Do you have blank spells which occur during the day?” (p = 0.02; 250 
OR = 4.066 (1.23-13.45)), and Q6a: “Is your pain worse in different parts of your body on 251 
different days?” (p = 0.04; OR = 3.73 (1.04-13.37)). Diagnostic utility (AUC) of sub-questions 252 
for each symptom were: blackouts = 0.94, weakness = 0.71, memory problems = 0.74, 253 
tremor = 0.63, pain = 0.66 and fatigue = 0.6.  254 
 255 
Aggregate symptom score modestly predicts functional classification. 256 
Scores from symptom sub-question modelling were input into an aggregate model with 257 
other symptoms, features of clinical history, sex and age. Variable coefficients for the 258 
resulting model are shown in Figure 3. Only adjusted pain score (p = 0.047) and adjusted 259 
blackout score (p = 0.02) achieved significance in the model, with odds ratios 26.80 (2.00-260 
359.59) and 40.15 (1.73-930.21) respectively. 261 
 262 
Resulting aggregate scores were capable of predicting functional disorder likelihood 263 
with modest utility (Figure 4) (AUC = 0.83) and “optimal” operating point, as determined by 264 
minimising false positive rate, resulting in specificity and sensitivity of 0.99 and 0.47 265 
respectively. Positive and negative predictive values were 0.94 and 0.79. The model 266 
accounted for little of the variability in the outcome (Adjusted R2 = 0.23) but performed 267 
better than the constant model (Chi-square test vs Constant model p < 0.001). 268 
 269 
Symptom ‘networks’ may aid in differentiating patients with a functional disorder. 270 
As sample size precluded interactional analysis between reported symptoms, and as FND 271 
encompasses a heterogenous collection of symptoms, we sought to characterise the 272 
possible predictive utility of symptom pairs, thereby providing a coarse assessment of 273 
symptom interaction. That is, if a patient reports more than one symptom what symptom is 274 
that likely to be? Are there basic ‘syndromes’ that particularly delineate patients with a 275 
functional disorder? Of the 110 possible bidirectional symptom pairings, patients classed as 276 
‘Largely/Completely’ functional were more likely to report one symptom after reporting 277 
another when compared to those classed as ‘Not at All/Somewhat’ in 76/110 pairings. This 278 
reflects the greater average symptom counts in this group. Figure 5 exhibits how fatigue 279 
plays a central role in these interactions, being reported by more than 80% of those also 280 
reporting: stutter, memory problems, pain, weakness, blackouts, globus, altered sensation, 281 
tremor and multiple medical problems. Only one symptom pair (P(Memory problems | 282 
Multiple medical problems)) reaches this threshold in those with symptoms not explained 283 
by a functional disorder and none do so when paired with fatigue. 284 
Discussion 285 
This is the first reported pilot of a general screening questionnaire to improve the pre-test 286 
probability of a diagnosis of functional neurological disorders. We found that the total 287 
number of symptoms, in the subset we investigate here, failed to distinguish cases from 288 
controls, replicating a previous study [27]. The addition of items in our novel questionnaire 289 
about features reportedly specific to functional disorders also commonly failed to 290 
distinguish patient groups in our sample. There were however some exceptions, where 291 
patients classified as having functional symptoms more commonly reported features of: 292 
Blackouts (having had a blackout in a medical setting, being able to hear people but not 293 
respond during a blackout, being upset following an episode); Memory problems (having 294 
associated blank spells during the day); Pain (reporting variability in bodily location and 295 
severity. 296 
 297 
Symptoms scores weighted according to these features in an aggregate model show 298 
good specificity (0.99) but poor sensitivity (0.47) when compared to consultant neurologist 299 
impression as measured on a 4-point Likert scale. Resulting positive and negative predictive 300 
values (0.94 and 0.79 respectively) were however, promising, and had greater utility as a 301 
pre-screening diagnostic tool for FND than measures based on symptom counts such as 302 
PHQ-15 [25,27]. Although more effective for excluding those deemed to have symptoms of 303 
an “organic” cause, our linear score failed to reliably identify patients with FND from a 304 
general neurology outpatient population. Our speculative assessment of symptom 305 
interactions suggests that non-linear methods that take account of multivariate higher order 306 
interactions may prove a more valuable approach.  307 
 308 
Eliciting self-reported positive features of functional disorders is challenging. 309 
Although many discriminating features of history have been described in the literature and 310 
anecdotally, our data show that these are difficult to translate into specific and sensitive 311 
questions for patients to answer in an unguided way. A comparative analysis of self-312 
reported vs clinical record extracted seizure features [52] recently highlighted that using a 313 
self-report questionnaire [29] is associated with a greater quantity of reported features, and 314 
greater detail regarding premonitory or triggering features as compared to clinician enquiry 315 
which was more effective at eliciting historical predictors. In keeping with our data, these 316 
questions also showed generally good specificities and poor sensitivities. The corollary being 317 
that although our understanding of the semiology and history of functional symptoms has 318 
improved, the ability to extract that from patients with a functional disorder in a meaningful 319 
way is still the remit of an experienced diagnostic interview and physical examination. This is 320 
reflected in diagnostic criteria for functional neurological symptoms disorder in DSM-5 321 
which mandates the importance of physical signs typical of the disorders, and not the 322 
subjective experience of the patient. 323 
 324 
Capturing the recognised linguistic features of FND descriptions is a core problem in 325 
constructing a viable self-reported screening questionnaire. There is now a significant body 326 
of work highlighting these discriminating features: Poor formulation effort [53], inconsistent 327 
metaphorical conceptualisation [54], and vague seizure experience descriptions in 328 
psychogenic non-epileptic seizures; preserved working memory, the ability to process 329 
compound questions and good recollection of personal information in functional memory 330 
disorders [55]; post-exertional malaise in fatigue [56]. However, those studies were all done 331 
on the basis of interactive conversation analysis. Self-report tools implicitly rely on a 332 
particular symptom being amenable to self-recognition. Transposing clinical observations 333 
into questions capable of eliciting introspection and ‘accurate’ response is a clear limitation 334 
to such an enquiry. It may be that questionnaire items need to be refined or that 335 
questionnaires are, themselves, too crude a tool. 336 
 337 
Perhaps a surprising finding in this population is that questions regarding functional 338 
symptoms such as globus and stutter show poor diagnostic utility in both univariate and 339 
multivariate analysis. Although globus and adult onset stutter are generally considered to 340 
relate to a functional disorder [57] they were reported with similar frequency in both 341 
functional and non-functional groups, albeit in small numbers. There were also interesting 342 
responses in those with symptoms unexplained by a functional disorder to questions that 343 
are commonly associated with functional disorders. For example, 8 out of 73 patients 344 
reported that they had numbness or altered sensation that made them feel ‘like your body 345 
is cut in half’ [44] and 5 out of 21 patients reported tearfulness after blackouts [18]. 346 
Questions about movement disorders also indicated the difficulty of using questionnaires to 347 
elicit a history. All 19 patients who reported an abnormal movement such as tremor in the 348 
structural group said it came on suddenly. But what a neurologist understands as sudden, 349 
for example not there at 10.58am and present at 11.00am – may not be the same as how a 350 
patient understands that word – ‘I didn’t have it last year and suddenly this year I do’. It was 351 
also surprising how many movement disorder patients said that their movements could go 352 
away for hours or days (16/19). 353 
 354 
The importance of diagnostic tools and more effective diagnostic procedures in FNDs 355 
A standardised and easily administrable tool for the screening of functional disorders has 356 
the potential to enhance clinicians’ pre-test probability for making a diagnosis of functional 357 
disorder and, as a consequence of earlier intervention, reduce iatrogenic harm. A shorter 358 
duration of symptoms prior to diagnosis often predicts a favourable prognosis in FNDs 359 
[2,14]. Early identification of patients with likely functional symptoms could also assist in 360 
quantifying their prevalence and demographics at an epidemiological scale. So far this has 361 




This was a pilot study of a new approach to FND diagnosis, with a relatively small sample 366 
size. Our reported predictive values are dependent on prevalence calculated on a relatively 367 
small population which, for certain symptoms, failed to meet the generally accepted rule of 368 
5-10 participants per predictor variable [58]. The large variances observed during linear 369 
modelling may be a reflection of this, or a reflection of the variable nature of functional 370 
disorders. There is a risk that some patients were classified in to the wrong diagnostic group 371 
by the neurologists seeing them, although a similar study found a very low rate of 372 
misdiagnosis at 18 months follow up [3]. We also don’t know whether, even if the 373 
neurologist rated the main diagnosis as “organic”, the symptom the patient gave their 374 
responses about would have received the same rating. We are also cautious to highlight the 375 
limitations of the present two-stage modelling. Ideally, sub-question coefficients should be 376 
computed on a separate population from the overall aggregate score to prevent a 377 
significant bias in favour of symptoms with sub-questions in the final model. 378 
 379 
Our final model is biased to a degree by case deletion of those with incomplete 380 
questionnaires. 109 individuals were included in the final analysis, with 56 (34%) of the 165 381 
participants excluded. Given this significant proportion, we sought to establish whether 382 
their inclusion in analysis might mitigate some of the bias case deletion introduces. As we 383 
first model symptom sub-questions on a subset of those reporting that symptom, we were 384 
able to include every participant who had at least answered a single symptom’s sub-385 
questions completely in the first stage of modelling. Using symptom scores derived from 386 
this more inclusive criterion, we then reran the aggregate model with the 109 respondents 387 
who had complete questionnaires. Resulting sub-question coefficients were similar with 388 
Q1d: “Have you ever been able to hear people but not respond to them during your 389 
blackout?” and Q4c: “Do you have blank spells which occur during the day?” remaining 390 
significant with p values in the new model 0.039 and 0.006 respectively. And Q6a: “Is your 391 
pain worse in different parts of your body on different days?” becoming less significant (p 392 
= 0.05).  In the final aggregate model, blackout scores become insignificant (OR = 7.97 (0.57-393 
111.68)) but pain scores remain predictive (OR = 21.87 (1.34-358.05). Aggregate scores 394 
however retain similar discriminate utility (AUC = 0.80) and sensitivity of 0.64 and specificity 395 
of 0.84 at the ‘optimal’ operating point. 396 
 397 
We also found that many of our questions, or question wordings, although 398 
constructed to elicit positive answers in those experiencing functional symptoms, failed to 399 
do so on many occasions. Only blackouts, memory problems and pain domains had sub-400 
questions answered significantly more often by patients deemed ‘Largely/Completely’ 401 
functional. The heterogeneity of both FND and neurological pathology in general may be the 402 
limiting factor to such a broad goal. Future approaches to this issue would require more 403 
rigorous testing of questionnaire comprehension, investigating educational background and 404 
reading level of the participants. It is clear that if the present tool is to be developed, and 405 
sensitivities greater than 0.47 are to be achieved, question wording and inclusion needs to 406 
be adjusted considerably.  407 
 408 
Readers may also wonder why we didn’t study the performance of the relevant 409 
subsections of the questionnaire for diagnostic categories (for example functional gait 410 
disorder, non-epileptic seizures). This was firstly because the numbers involved would have 411 
been too small and secondly because patients with functional neurological disorders often 412 
have mixed symptoms which are not always picked up on diagnostically by neurologists.  413 
 414 
Conclusions 415 
Despite limitations, this pilot version of an ENS questionnaire was, in its complete form, 416 
surprisingly capable of reliably excluding patients diagnosed by neurologists as not having a 417 
functional disorder. Although showing utility in capturing functional/dissociative blackouts, 418 
we failed to distinguish many other symptoms, highlighting the linguistic and interpretive 419 
difficulties in eliciting functional vs structural symptom experience. The use of specific 420 
positive features of functional disorder in an aggregate model rather than linear summation 421 
of symptom counts has shown promising utility. Future work could aim to investigate more 422 
systematically how those who experience functional symptoms, outside the domain of 423 
blackouts, report their disorder and therefore how to improve question wording. 424 
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Table 1 446 
 447 
Q11: Have you needed any operations? 0.4216/36 (44%)40/73 (55%)
Q10: Do you have a stutter which started after you were more than 16 years old? 0.683/36 (8%)4/73 (5%)
Q9: Do you get a feeling that there is a lump in your throat or something stuck when
you are trying to eat or drink? >0.998/36 (22%)18/73 (25%)
0.5316/36 (44%)27/73 (37%)
Q8: In the last five years have you had to see doctors in the hospital for different
problems more than four times? (E.g. problems with your heart, your joints, your
brain and gut)
Q7: Have you been lacking energy every day or almost every day for the last six
months?
0.02*28/36 (78%)40/73 (55%)
Q7a: Does activity make your fatigue worse? 0.1123/28 (82%)25/40 (63%)
Q6: During the last three months have you had pain almost every day in more than
one part of your body? 0.007**22/36 (61%)24/73 (33%)
Q6a: Is your pain worst in different parts of your body on different days? 0.04*16/22 (73%)10/24 (42%)
0.03*17/36 (47%)19/73 (26%)Q5: During the last six months have you been bothered by tremor or an abnormalmovement in one or more limb e.g. arm (s) or leg(s)?
0.2215/17 (88%)19/19 (100%)Q5a: Did your tremor or abnormal movement come on suddenly?
0.653/17 (18%)2/19 (11%)Q5b: Did your tremor or abnormal movement come on after an injury oraccident?
0.6116/17 (94%)16/19 (84%)Q5c: Can your tremor or abnormal movement go away completely for hoursto days only to return again?
0.435/17 (29%)3/19 (16%)Q5d: Does your tremor or abnormal movement ever stop when you aredistracted or concentrating on something else?
Q4: During the last six months have you been bothered by memory problems? 0.5422/36 (61%)39/73 (53%)









Q4b: Are you bothered by forgetting important details such as the name of a
family member or your PIN number? 0.1814/22 (64%)17/39 (44%)
Q4c: Do you have blank spells which occur during the day? 0.007**15/22 (68%)12/39 (31%)
Q3: Do you have numbness or altered sensation that makes you feel like your body
is cut in half? 0.02*11/36 (31%)8/73 (11%)
0.2220/36 (56%)30/73 (41%)Q2: During the last six months have you been bothered by weakness in one or morelimb e.g. arm(s) or leg(s)?
0.1613/20 (65%)13/30 (43%)Q2a: Do you drop things frequently?
>0.9910/20 (50%)14/30 (47%)Q2b: Does your limb weakness get worse or better at different times of the
day?
0.119/20 (45%)6/30 (20%)Q2c: Does concentrating on trying to move make the limb weakness worse?
0.2410/20 (50%)9/30 (30%)Q2d: At the start of your limb weakness did you feel your heart pounding ordid you feel frightened, anxious or very uneasy?
0.5711/20 (55%)13/30 (43%)Q2e: Does your weak limb feel like it does not fully belong to you?
Q1: During the last 6 months have you been bothered by blackouts? 0.839/36 (25%)21/73 (29%)
Lie Still: 5/21 (24%)
Shake: 13/21 (62%)
Unsure: 3/21 (14%)
Lie Still: 3/9 (33%)
Shake: 4/9 (44%)
Unsure: 2/9 (22%)
0.67Q1a: During you blackouts do you get told you lie still or shake?
0.005**5/9 (56%)1/21 (5%)Q1b: Have you ever had a blackout in a medical setting e.g. visiting thehospital/GP/another doctor?
0.562/9 (22%)2/21 (10%)
Q1c: Have you had more than two seizures during which you shook without
stopping for more than 10minutes? (This does not include the time taken for you
to come round after the seizure had finished)
0.002**8/9 (89%)5/21 (24%)Q1d: Have you ever been able to hear people but could not respond to themduring your blackout?
0.079/9 (100%)13/21 (62%)
Q1e: Do you ever have moments before your blackouts of losing track of what is
going on, of “blanking out” or “spacing out” or in some way feeling that you are
not part of what is going on?
0.04*6/9 (67%)5/21 (24%)Q1f: Are you told that after an attack you cry or are upset?
N 36/109 (33%)73/109 (67%)
0.01*Sex F:M = 3.5:1F:M = 1.09:1
Age (Mean ± SD) 0.2041.6 ± 16.246 ± 17.5
Symptom Count (Mean ± SD) 0.008**3.15 ± 2.07 4.33 ± 2.27
Gross ENS Score (Mean ± SD) 0.003**7.95 ± 5.48 11.69 ± 7.27
p-valueLargely/CompletelyNotatAll/Somewhat
Symptomsexplainedbya func�onaldisorder:
Figure 1 448 
 449 
Figure 1: Comparison of gross scores. A - Boxplot of symptom counts separated by 450 
functional classification. Symptom counts are significantly greater in patients with functional 451 
disorder. B - Boxplot of gross scores for full 30-point ENS questionnaire. The addition of 452 
discriminating sub-questions yields greater scores for ‘Largely/Completely’ explained by 453 
functional disorder. C - ROC curve of symptom count and gross sum. Symptom count and 454 
raw ENS scores fail to provide diagnostic utility (N/S = Not at All/Somewhat; L/C = 455 
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Figure 2 467 
 468 
Figure 2: Results of multivariate sub-question analysis. Sub-questions were input as 469 
predictor variables and the resulting coefficients, confidence intervals and odds ratios are 470 
displayed above. Only Q1d, Q4c and Q6a achieve significance in their respective models. 471 
Most sub-questions provide, as expected, a positive predictive value for functional 472 
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Figure 3 479 
 480 
Figure 3: Aggregate score coefficients. Forest plot showing linear coefficients and 481 
confidence intervals for each variable in the aggregate model. “Common” symptoms have 482 
been replaced by the linear predictor scores from sub-question modelling. Odds ratios are 483 
displayed for each coefficient above the bar. Adjusted scores for pain and blackouts achieve 484 
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Figure 4 487 
 488 
Figure 4: Diagnostic utility of the ENS questionnaire. A - ROC curve of aggregate linear 489 
model scores predicting consultant classification of patients with symptoms ‘Not at 490 
All/Somewhat’ or ‘Largely/Completely’ functional. The optimal operating point is displayed 491 
as a red circle on the curve. Predictor scores were capable of achieving an AUC of 0.83. B - 492 
Scatter plot of aggregate model scores separated by functional classification. The 493 
corresponding optimal score identified in ROC analysis is displayed as a grey dotted line. The 494 
model is capable of excluding patients with a pathophysiological disorder effectively, but 495 












































Figure 5 507 
 508 
 509 
Figure 5: Symptom interactions. Paired conditional probabilities of symptoms occurring if 510 
another symptom is reported. Red lines indicate a symptom pair in which there is a more 511 
than 80% likelihood of a co-occurrence. Grey lines indicate co-occurrence > 0.5 and are 512 
weighted linearly between 0.5-0.8. Patients with functional disorders reported symptom 513 
networks that are far more connected than patients with a pathophysiological disorder. 514 
Fatigue is more commonly reported as a comorbidity in patients with a functional rather 515 
than structural disorder. (Red: Functional class = ‘Largely/Completely’; Blue: Functional class 516 
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Neurological Symptom Questions 
Many people experience neurological symptoms. These can be disabling and distressing. This 
survey asks about common neurological symptoms you may be experiencing. 
1.  During the last six months have you been bothered by blackouts? 










 b. Have you ever had a blackout in a medical setting e.g. visiting the hospital/GP/another doctor? ¨1 ¨0 
 c. Have you had more than two seizures during which you shook without stopping for more than 10minutes?  (This does not include 
the time taken for you to come round after the seizure had finished) 
¨1 ¨0 
 d. Have you ever been able to hear people but could not respond to them during your blackout? 
¨1 ¨0 
 e. Do you ever have moments before your blackouts of losing track of what is going on, of “blanking out” or “spacing out” or in some way 
feeling that you are not part of what is going on? 
¨1 ¨0 
 f. Are you told that after an attack you cry or are upset? ¨1 ¨0 
2.  During the last six months have you been bothered by weakness in one or 
more limb e.g. arm(s) or leg(s)? 





 a. Do you drop things frequently? ¨1 ¨0 
 b. Does your limb weakness get worse or better at different times of 
the day? ¨1 ¨0 
 c. Does concentrating on trying to move make the limb weakness 
worse? 
¨1 ¨0 
 d. At the start of your limb weakness did you feel your heart pounding 
or did you feel frightened, anxious or very uneasy? 
¨1 ¨0 
 e. Does your weak limb feel like it does not fully belong to you? ¨1 ¨0 
3.  Do you have numbness or altered sensation that makes you feel like your 





4.  During the last six months have you been bothered by memory problems? 













 b. Are you bothered by forgetting important details such as the name 
of a family member or your PIN number? 
¨1 ¨0 




5.  During the last six months have you been bothered by tremor or an 
abnormal movement in one or more limb e.g. arm (s) or leg(s)? 





 a. Did your tremor or abnormal movement come on suddenly? ¨1 ¨0 
 b. Did your tremor or abnormal movement come on after an injury or 
accident? 
¨1 ¨0 
 c. Can your tremor or abnormal movement go away completely for 
hours to days only to return again? ¨1 ¨0 
 d. Does your tremor or abnormal movement ever stop when you are 
distracted or concentrating on something else? ¨1 ¨0 
6.  During the last three months have you had pain almost every day in more 
than one part of your body? 





 a. Is your pain worst in different parts of your body on different days? ¨1 ¨0 
7.  Have you been lacking energy every day or almost every day for the last 
six months? 





 a. Does activity make your fatigue worse? ¨1 ¨0 
8.  In the last five years have you had to see doctors in the hospital for 
different problems more than four times? 





9.  Do you get a feeling that there is a lump in your throat or something stuck 

















Appendix   Tonsils     Laparoscopy to investigate pain        Hysterectomy  
 




1.                                                     2.                                                  3. _______________________                                               
 
Thank you for filling out the questionnaire 
Appendix B: Consultant diagnostic guidance 760 
“What we mean by a functional disorder 761 
The following is meant as a guide for this study and we are aware that any divisions like 762 
this are imperfect. Many patients have a mixture of symptoms, syndromes or disease and 763 
the final coding is your decision based on these guidelines 764 
 765 
‘Functional disorder’ for the purpose of this study: Tension Headache; Aetiologically 766 
controversial symptom ‘syndromes’ (e.g. Chronic fatigue syndrome, Fibromyalgia, Irritable 767 
Bowel Syndrome); Physiologically explained processes which are thought to be linked to 768 
emotional symptoms (e.g. Hyperventilation); Chronic pain or dizziness which is 769 
unexplained by a clear structural cause. 770 
 771 
‘Organic disease’ for the purpose of this study: Migraine; Any neurological disorder with 772 
a known pathological basis; Neurological disorders with defined and characteristic 773 
features but without a clear pathological basis (e.g.  Gilles de la Tourette syndrome, 774 
Idiopathic focal dystonia); Physiological explained processes NOT linked to emotional 775 
symptoms (e.g. micturition syncope); Psychotic disorder.” 776 
 777 
 778 
 779 
